Trigene Pharmaceuticals India Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
as on 05-01-2025
- Paid Up Capital ₹ 0.10 M
as on 05-01-2025
- Company Age 7 Year, 1 Month
- Last Filing with ROC 31 Mar 2024
- Revenue 111.83%
(FY 2020)
- Profit 113.76%
(FY 2020)
- Ebitda 55.30%
(FY 2020)
- Net Worth 41.45%
(FY 2020)
- Total Assets -2.72%
(FY 2020)
About Trigene Pharmaceuticals India
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Jitendra Mishra, Mamta Mishra, and Shweta Shukla serve as directors at the Company.
- CIN/LLPIN
U74999MH2017PTC302722
- Company No.
302722
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
11 Dec 2017
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- LocationThane, Maharashtra
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Trigene Pharmaceuticals India?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Jitendra Mishra  | Director | 07-Nov-2020 | Current |
| Mamta Mishra | Director | 07-Nov-2020 | Current |
| Shweta Shukla | Director | 02-Dec-2020 | Current |
Financial Performance of Trigene Pharmaceuticals India.
Trigene Pharmaceuticals India Private Limited, for the financial year ended 2020, experienced significant growth in revenue, with a 111.83% increase. The company also saw a substantial improvement in profitability, with a 113.76% increase in profit. The company's net worth Soared by an impressive increase of 41.45%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Trigene Pharmaceuticals India?
In 2020, Trigene Pharmaceuticals India had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Vocloc Enterprises Private LimitedActive 3 years 9 monthsJitendra Mishra and Mamta Mishra are mutual person
- Meteoralabs Private LimitedActive 8 years 4 months
Jitendra Mishra and Mamta Mishra are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Trigene Pharmaceuticals India?
Unlock and access historical data on people associated with Trigene Pharmaceuticals India, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Trigene Pharmaceuticals India, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Trigene Pharmaceuticals India's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
